Patents by Inventor Tamara THELEMANN

Tamara THELEMANN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Immunosuppression-reverting oligonucleotides inhibiting the expression of CD39
    Patent number: 11959083
    Abstract: The present invention refers to immunosuppression-reverting oligonucleotides comprising 12 to 18 nucleotides, wherein at least one of the nucleotides is modified, and the oligonucleotide hybridizes with a nucleic acid sequence of an ectonucleotidase (NTPdase; CD73) of SEQ ID NO.1 (human), wherein the oligonucleotide inhibits at least 50% of the CD39 expression. The invention is further directed to a pharmaceutical composition comprising such oligonucleotide.
    Type: Grant
    Filed: October 9, 2017
    Date of Patent: April 16, 2024
    Assignee: Secarna Pharmaceuticals GmbH & Co. KG
    Inventors: Frank Jaschinski, Tamara Thelemann
  • Antisense oligonucleotides for inhibition of PD-L1 expression and treating cancer
    Patent number: 11666595
    Abstract: The present invention relates to a novel approach for treating cancer, which is based on targeting PD-L1 mRNA. The invention is directed to oligonucleotides comprising 10 to 20 modified or unmodified nucleotides complementary to specifically selected regions of the PD-L1.
    Type: Grant
    Filed: October 6, 2017
    Date of Patent: June 6, 2023
    Assignee: Secarna Pharmaceuticals GmbH & Co. KG
    Inventors: Tamara Thelemann, Frank Jaschinski, Richard Klar
  • PD-L1 antisense oligonucleotides for use in tumor treatment
    Publication number: 20220220485
    Abstract: The present invention refers to an oligonucleotide consisting of 10 to 20 nucleotides hybridizing with SEQ ID NO.1 encoding PD-L1, wherein the oligonucleotide has a fundamentally reduced number of potential off-target binding sites resulting in a markedly reduced risk for off-target effects. Further, the present invention is directed to a pharmaceutically composition comprising such oligonucleotide and a pharmaceutically acceptable excipient.
    Type: Application
    Filed: May 4, 2020
    Publication date: July 14, 2022
    Inventors: Frank JASCHINSKI, Richard KLAR, Tamara THELEMANN, Sven MICHEL
  • Immunosuppression-Reverting Oligonucleotides Inhibiting the Expression of CD39
    Publication number: 20200224202
    Abstract: The present invention refers to immunosuppression-reverting oligonucleotides comprising 12 to 18 nucleotides, wherein at least one of the nucleotides is modified, and the oligonucleotide hybridizes with a nucleic acid sequence of an ectonucleotidase (NTPdase; CD73) of SEQ ID NO.1 (human), wherein the oligonucleotide inhibits at least 50% of the CD39 expression. The invention is further directed to a pharmaceutical composition comprising such oligonucleotide.
    Type: Application
    Filed: October 9, 2017
    Publication date: July 16, 2020
    Inventors: Frank JASCHINSKI, Tamara THELEMANN